MX2021004965A - Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida. - Google Patents

Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida.

Info

Publication number
MX2021004965A
MX2021004965A MX2021004965A MX2021004965A MX2021004965A MX 2021004965 A MX2021004965 A MX 2021004965A MX 2021004965 A MX2021004965 A MX 2021004965A MX 2021004965 A MX2021004965 A MX 2021004965A MX 2021004965 A MX2021004965 A MX 2021004965A
Authority
MX
Mexico
Prior art keywords
solid dispersion
amorphous solid
acryloylpiperidin
phenoxyphenyl
nicotinamide
Prior art date
Application number
MX2021004965A
Other languages
English (en)
Inventor
Xiangyang Chen
Zuopeng Wang
Liqin Yu
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of MX2021004965A publication Critical patent/MX2021004965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una dispersión sólida amorfa que comprende la 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifenil)nic otinamida (Compuesto I), o una sal farmacéuticamente aceptable de esta, y un polímero farmacéuticamente aceptable. La presente invención también se refiere a composiciones farmacéuticas que comprenden la dispersión sólida amorfa. La dispersión sólida amorfa de la presente invención es estable durante el almacenamiento y provee una mejor tasa de disolución y biodisponibilidad cuando se compara con una forma cristalina.
MX2021004965A 2018-11-06 2019-10-28 Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida. MX2021004965A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862756464P 2018-11-06 2018-11-06
PCT/CN2019/113636 WO2020093896A1 (en) 2018-11-06 2019-10-28 Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Publications (1)

Publication Number Publication Date
MX2021004965A true MX2021004965A (es) 2021-06-15

Family

ID=70611726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004965A MX2021004965A (es) 2018-11-06 2019-10-28 Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida.

Country Status (11)

Country Link
US (1) US20210260050A1 (es)
EP (1) EP3876911A4 (es)
JP (1) JP2022506622A (es)
KR (1) KR20210090201A (es)
CN (1) CN113038936B (es)
AU (1) AU2019376368A1 (es)
CA (1) CA3117009A1 (es)
MX (1) MX2021004965A (es)
SG (1) SG11202103861YA (es)
TW (1) TWI826570B (es)
WO (1) WO2020093896A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521763A (ja) * 2019-02-25 2022-04-12 ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド ６－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）ニコチンアミドの製造方法
CN115894440A (zh) * 2022-10-27 2023-04-04 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
SG11201602070TA (en) * 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
US9533991B2 (en) * 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41197B1 (fr) * 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
HUE061809T2 (hu) * 2014-12-24 2023-08-28 Principia Biopharma Inc Készítmények csípõbél-éhbél szakaszba történõ hatóanyag beadáshoz
CN105816423B (zh) * 2016-03-16 2018-07-20 福建天泰医药科技有限公司 依达拉奉剂型
CN107308133A (zh) * 2016-04-27 2017-11-03 周意 姜黄素药物制剂
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer

Also Published As

Publication number Publication date
US20210260050A1 (en) 2021-08-26
CN113038936A (zh) 2021-06-25
CN113038936B (zh) 2023-05-02
TW202017917A (zh) 2020-05-16
CA3117009A1 (en) 2020-05-14
TWI826570B (zh) 2023-12-21
EP3876911A4 (en) 2022-06-22
EP3876911A1 (en) 2021-09-15
JP2022506622A (ja) 2022-01-17
AU2019376368A1 (en) 2021-06-03
SG11202103861YA (en) 2021-05-28
WO2020093896A1 (en) 2020-05-14
KR20210090201A (ko) 2021-07-19

Similar Documents

Publication Publication Date Title
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
CR20210061A (es) Composiciones farmacéuticas que comprenden meloxicam
EP3991731A4 (en) FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLIC PYRIMIDINE DERIVATIVE, PROCESS FOR ITS PREPARATION AND ITS PHARMACEUTICAL USE
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
WO2016023954A3 (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
ZA202204206B (en) Pesticidally active fused bicyclic heteroaromatic compounds
HK1249502A1 (zh) 吡啶並[3，4-d]嘧啶衍生物及其藥學上可允許的鹽
PH12016501825A1 (en) Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2016205738A3 (en) Delivery systems for controlled drug release
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
JOP20190174B1 (ar) مثبطات jak1 انتقائية
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
MX2020007552A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
EP3705478A4 (en) TRIAZINE COMPOUND AND PHARMACEUTICAL SALT THEREOF
MX2021004965A (es) Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida.
CA2904820C (en) Pyridinylpyrazoloquinoline compound
MX355885B (es) Composición farmacéutica de administración oral.
EP3694330A4 (en) INDAZOLYL-SPIRO [2.2] PENTANCARBONITRIL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES
WO2015000431A9 (zh) 替唑尼特氨基甲酸酯及其在药学中的应用
EP3488845A4 (en) FORMULATION HAVING IMPROVED PH-BASED MEDICATION RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF